Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
I’m talking about AVA6000. What if they can eradicate tumours by saturating the tumour so no surgery is needed. There are lots of papers on successfully saturating inoperable tumours effectively but by costly procedures using catheters to inject the tumours. Ava6000 is doing the same as it is targeted. Also it would mean inoperable tumours high in FAP become survivable diagnosis instead of terminal diagnosis.
Surgery might be a thing of the past for some cancers because of Precisions targeted action. They might find they can saturate the tumour with a MTD and the tumour is destroyed without damaging the body.
Paul him reckons between £3.30 and£5 on this news https://twitter.com/capitalpmh/status/1615246845512486912?s=46&t=vS2TRQndxnqu4litKrWTqw
I’m amazed at 6 biopsies, it is well documented that it is very difficult to get any when they are not mandatory as it’s not straight forward.
I’m with Doggy, I’m emotional because my younger sister could’ve possibly lived if she had ava6000. Standard Dox total dose did reduce her tumour to nearly a size they could remove it but it was too late as the cancer spread. Who knows if she had a higher dose from the offset . Her 4 young kids would still have their mum. Thank you to all the brave participants in the trial. Thank you Avacta.
Thanks Energy shares. More great news.
The AFX platform.
AffyXell Therapeutics Co., Ltd. (CEO: Seungho Jeon, and Jong Sang Ryu) is a next-generation cell & gene therapy development company founded in January 23rd, 2020 as a joint venture by Daewoong Pharmaceuticals and Avacta Life Science, U.K.
We are developing next generation cell & gene therapeutics (AFX platform technology) for optimized for immunomodulation of diseases. The AFX platform technology is new modality of cell & gene therapeutics that based on advanced mesenchymal stem cells which to overcome the limitations of tissue-derived mesenchymal stem cells and adopted Affimer platform technology by genetic manipulations for improve immunomodulation function.
Excellent find ES.
“ In some aspects, are therapeutic conjugates designed to release a therapeutically effective amount of a drug (or other therapeutic moiety) in a tumor microenvironment of a subject without inducing acute toxicity in the subject. Surprisingly, the conjugates of the present disclosure are capable of local delivery of a therapeutically effective amount of a drug, even in the absence of a cell-binding (e.g., targeting) moiety. Instead of a targeting moiety or other cell-specific homing mechanism, the conjugates of the present disclosure include a half-life extension moiety and a cleavable linker that enables local accumulation and release of the drug (or other therapeutic moiety) specifically in a tumor microenvironment. The half-life extension moiety enables local accumulation of the drug, while the specificity is achieved using a cleavable linker that is cleaved specifically by FAPa - an enzyme present at high levels in tumor microenvironments. Thus, specific cleavage of the linker by FAPa results in local release of a therapeutically effective amount of the drug in a tumor microenvironment, without the toxic side effects typically associated with systemic delivery of the drug.
I think it’s true. Live data account discovered and shared the orphan drug designation info prior to the rns about it. Infact I believe the rns came about because of their post. Live data account is a super sleuth.
Where biopsy is not mandatory for a trial it is well documented that participants in clinical trials are not forthcoming in giving biopsies. These patients are terminal and their time is extremely precious and they have been through enough. Taking a biopsy is not straight forward and there is a lot of red tape also.
Fiona said they would use archival biopsies in the video interview with Paul hill. They are confident they will get some during the trial. I think it’s prudent not to put too much emphasis on biopsies at this point.
Paul Hill asks the same question in the You tube interview from 7 months back. Listen 18 minutes in. Briefly FAP in plasma is transient and in arthritis and post op FAP appears transient and doesn’t appear active. They are targeting active FAP, which is what differentiates FAP in cancer. They talk also about personalised chemo. They are clearly looking at that. Best to listen to her explain.
n the U.S., the orphan drug designation confers several benefits. First, companies get a tax credit worth up to 50% of the medicine's research and development (R&D) costs. Second, orphan drug projects often receive grants for up to several million dollars to subsidize each phase of clinical trials, which gives smaller companies a chance to make medicines for rare diseases without worrying as much about hefty costs. Finally, manufacturers of orphan drugs are entitled to seven years of marketing exclusivity, and an orphan drug indication does not preclude companies from seeking out larger drug indications in the future.
It’s in the public domain on the USA trademark site. Here is the link. There are many documents, for ease read the publication and the granting of trademark on June 13th. They then have to publish it for 30 days in a gazette and then if no opposition it’s official. There has been no opposition so it was granted. https://tsdr.uspto.gov/#caseNumber=79304130&caseType=SERIAL_NO&searchType=statusSearch
The AffiDX trademark from tomorrow 14 July is live in USA. Avacta agreed a contract with the company whose mark they were supposed to be similar to. The US office accepted the contract and granted the trademark for both AffiDX and Affirx trademark. The marks were published in June and tomorrow they go live.
I agree with CO , They might be getting benefit at much lower dosing, while better reducing and mitigating systemic exposure.
It’s not a case just because something is working that you give them as much as possible. That is what has happened in medicine in the past and it left people with unnecessary side effects, and other issues, they now realise it is not the best course of action and medical treatments are changing to reflect that.
Speculation, but would tie in with the successful publication of the Affidx trademark this month. Why spend all that money and time in the USA successfully fighting the initial tradeMark decision so they can use the AFFIDX branding in the USA.
Then this email from Abingdon health this morning
“ Abingdon Health has been working behind the scenes on the launch of something new - that we know you'll love!
Whilst we can't give away too much right now, very soon you'll have a brand new place to find and buy home self-tests that enable you to look after your health, at a time and place that's convenient for you.
And the best bit - all products have been validated by Abingdon Health.”